The Pharma Data

JANUARY 31, 2021

Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

OCTOBER 14, 2020

The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The research encompasses two projects. The study led by Dr. Ilya Trakht, Ph.D., About TNX-1800. 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 14, 2020

I’m very excited by the opportunities presented by BetterLife’s experienced clinical research team enabling Transcend’s novel therapeutics to reach human beings in need of help.”. The regulatory hurdles and barriers associated with administering psychedelics to human subjects are staggering.

Bioethics 40

Bioethics Clinical Research Regulations Clinical Trials 40

Agency IQ

JANUARY 12, 2024

These windows depend on whether the new drug application (NDA) or biologics license application (BLA) is a new molecular entity, and if the application has received standard review (10 months, plus 2 months of administrative time) or priority review (6 months, plus 2 months of administrative time).

FDA 40

FDA Drugs Production Licensing 40

The Pharma Data

NOVEMBER 9, 2020

Results from the NAVIGATOR trial will be presented at an upcoming medical meeting. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Type 2 inflammation in asthma–present in most, absent in many. J Allergy Clin Immunol. 2014; 133: 388–94. 15 Fahy JV.

Trials 52

Trials Production Clinical Trials Government 52

Agency IQ

JUNE 29, 2023

Prescription drug advertisements presented through media such as TV and radio must disclose the product’s major side effects and contraindications in what is sometimes called the major statement. This rule also establishes standards for determining whether the major statement in these advertisements is presented in the manner required.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

DECEMBER 5, 2020

The results were shared in an oral presentation at the virtual 2020 American Society of Hematology (ASH) Annual Meeting. (NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma.

Production 40

Production Trials Treatment Disease 40

The Pharma Data

OCTOBER 29, 2020

We are also focused on minimizing potential interactions that could contribute to the spread of the virus and put additional strain on healthcare systems through the use of innovative virtual means where possible. ALXN2060 (AG10) – Eidos: Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan.

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

The Pharma Data

DECEMBER 21, 2020

Detailed results from the SOURCE trial will be presented at a future medical meeting. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Further analyses of the data are ongoing. The safety profile of tezepelumab in the trial was consistent with previous trials.

Trials 40

Trials Production Clinical Trials Therapies 40

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Published June 27, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Biocryst and Peter Marks, as well as updates from UCB and Altimmune that you may have missed. An oral solution of fenfluramine is already cleared in the U.S.

Vaccine 130

Vaccine FDA Therapies Licensing 130

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 136

Therapies Virus DNA Clinical Trials 136

Agency IQ

MARCH 7, 2024

BY AMANDA CONTI | MAR 6, 2024 8:46 PM CST AgencyIQ’s quick primer on the influenza virus and how annual vaccine strains are selected Influenza viruses have caused untold illness and death through human history. A key part of the influenza virus’ ability to infect humans is hemagglutinin (HA), a glycoprotein found on the surface of the virus.

Vaccine 40

Vaccine FDA Virus Licensing 40

The Pharma Data

JANUARY 21, 2021

Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

NOVEMBER 5, 2020

“Last week, Regeneron achieved an important milestone in the fight against COVID-19 with prospective Phase 2/3 results showing REGN-COV2 significantly reduced virus levels and the need for further medical attention in non-hospitalized patients; we have shared these important data with regulatory authorities,” said Leonard S.

Production 40

Production FDA Trials FDA Approval 40

Agency IQ

OCTOBER 27, 2023

Government shutdown: At present, the U.S. Prescription drug advertisements presented through media such as TV and radio must disclose the product’s major side effects and contraindications in what is sometimes called the major statement. Expect nearly every company to be closely reading this document when it’s eventually published.

FDA 40

FDA Science Regulations Production 40

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. This paper presents a massive CRISPR screen, in Arabidopsis, that identifies many genes with previously "hidden functions." Only about 15% of antibodies actually neutralize the new variants. Ricciardi M.J. Nature Plants.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

MARCH 11, 2021

We are in an excellent position to take advantage of the opportunities these dynamics present – for the benefit of the people who use our products and, through sustainable growth, for the benefit of our stockholders,” said Baumann.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Patients with severe COVID-19 infection often present with acute severe inflammation and organ failure.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Type 2 inflammation in asthma–present in most, absent in many. Amgen (NASDAQ:AMGN) announced that the U.S. Available at: [link] [Last accessed: April 2021]. Nat Rev Immunol.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

NOVEMBER 29, 2020

The webcast and the presentation will be available within the Investors & Media section of HOOKIPA’s website at [link]. 3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. Preliminary analyses show similar adverse events in the placebo and treatment arms.

Trials 52

Trials Virus Long-Term Care Facilities Government 52

The Pharma Data

JANUARY 18, 2021

A live webcast of this presentation will be available for registered participants at: [link]. This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. Riley Securities Oncology Investor Conference being held virtually.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

OCTOBER 12, 2021

Full results from Paraphernalia will be submitted for publication in a peer- reviewed medical journal and presented at a forthcoming medical meeting. AZD7442 AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.

Trials 52

Trials Treatment Virus Disease 52

The Pharma Data

DECEMBER 27, 2020

Infections due to hepatitis B virus (HBV) reactivation have occurred. Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia and other infections according to standard of care in patients who are at increased risk for infections. The most common Grade 3 or higher infection was pneumonia.

Production 52

Production Therapies Drugs Treatment 52

DrugBank

JUNE 18, 2025

Once a drug completes Phase III trials, companies prepare a New Drug Application or Biologics License Application (BLA) for final review. Many agencies offer pre-IND meetings where companies can present their research plans, discuss potential challenges, and receive guidance on the type of data required for approval.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

Codon

JULY 27, 2023

“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000. ” The tool was crafted with a virus, called GIL16.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000. ” The tool was crafted with a virus, called GIL16.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

SEPTEMBER 29, 2024

Simple ones, but still… This presented the student with a tantalizing future: the ability to fully model how a cell reacted to genetic perturbations. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. Of particular interest was how genetic therapies were delivered.

Engineering 144

Engineering Virus DNA Therapies 144

The Pharma Data

DECEMBER 23, 2020

Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. Elsewhere around the world: Avacta Group – U.K.-based

Licensing 52

Licensing Licensing Vaccine Drugs 52

The Pharma Data

SEPTEMBER 15, 2020

New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Published June 23, 2025 Delilah Alvarado Staff Reporter post share post print email license A micrograph image of influenza A virus. Influenza A virus" [Micrograph]. Retrieved from Flickr. Flu infections can also be deadly in young children , the elderly and people with underlying health conditions.

Drugs 264

Drugs Virus Therapies FDA 264

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. Merck presented long-term findings from the EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA as adjuvant therapy in resected, high-risk stage III melanoma at the ESMO Virtual Congress 2020. Non-GAAP EPS of $1.74

Vaccine 40

Vaccine Trials Treatment Virus 40

Agency IQ

SEPTEMBER 29, 2023

Prescription drug advertisements presented through media such as TV and radio must disclose the product’s major side effects and contraindications in what is sometimes called the major statement. This rule also establishes standards for determining whether the major statement in these advertisements is presented in the manner required.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. Due to the rapidly evolving and geographically diverse nature of the SARS-CoV-2 virus, continued scientific innovation remains critical to develop additional treatments. In the U.S.,

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Drug Target Review

JULY 19, 2023

Together these factors present an unsolved grand challenge in global health; one that has stubbornly resisted decades of effort and investment. Translating these insights into a licensed vaccine (RTS,S, made by GlaxoSmithKline) took nearly five decades – a glacial pace compared to the recent COVID-19 vaccines.

Vaccine 96

Vaccine Disease Engineering Virus 96